AKL, a company developing an investigational osteoarthritis (OA) medicine, has announced the appointment of Michael Martin as its Chief Financial Officer.
With more than 40 years’ global corporate finance experience advising companies in Mergers & Acquisitions, Initial Public Offerings and private equity, Mr Martin brings a wealth of deal experience to the AKL management team.
His appointment comes as AKL enters its next phase of bringing APPA, its investigational OA medicine which is currently in Phase I clinical trials at Liverpool University, to market.
AKL CEO David Miles, says: “Michael joins us at an important time both in the development of APPA and the company. His extensive corporate finance experience will be invaluable as we seek to grow AKLRD both organically and through partnerships.”
Mr Martin says: “I am thrilled to join AKL’s leadership team at what I believe is a pivotal stage in the company’s growth and look forward to contributing to its future success.”